Home / Generics / News / European approval for fluticasone/salmeterol and gefitinib generics

European approval for fluticasone/salmeterol and gefitinib generics Posted 12/10/2018

Indian generics maker Glenmark Pharmaceuticals (Glenmark) announced on 10 September 2018 that its subsidiary Glenmark Arzneimittel had secured marketing authorization in Germany for its generic fluticasone/salmeterol dry powder inhaler (DPI).

Fluticasone/salmeterol is an inhaled drug used to treat asthma and chronic obstructive pulmonary disease (COPD).

Glenmark’s product, which will be called Salflutin (fluticasone/salmeterol) in Germany, is a generic version of GlaxoSmithKline’s (GSK) asthma inhaler Seretide/Advair Accuhaler (fluticasone/salmeterol). It will be the company’s first inhalation product available in Germany. A fact that it says ‘validates Glenmark’s capabilities in the complex inhaled respiratory products segment’.

Glenmark entered into a strategic development and licensing agreement with Celon Pharma in 2015 to develop and market generic fluticasone/salmeterol DPI in 15 European countries.

The company has already launched this product in Denmark, Sweden and Norway. According to IQVIA data, fluticasone/ salmeterol DPI had sales of US$844 million in Europe in the 12-month period ended March 2018.

US generics manufacturer Mylan launched the first bioequivalent alternative to GSK’s Seretide/Advair Accuhaler in the UK back in June 2015 [1].

Generic gefitinib tablets have been approved in Europe and a generic fluticasone/salmeterol dry powder inhaler has been approved in Germany.

US generics company Alvogen announced on 5 September 2018 that it had successfully concluded multiple registration applications for generic gefitinib tablets.

Gefitinib is a drug used to treat certain breast, lung and other cancers. The originator product, AstraZeneca’s Iressa (gefitinib), had global sales of US$528 million and European sales of US$136 million in 2017.

Alvogen’s gefitinib is a fully generic and bioequivalent version of Iressa tablets and has been fully developed in-house. The drug is indicated for non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK). Gefitinib was developed by Lotus Pharmaceuticals, an Alvogen affiliate. Marketing authorizations have been filed by Alvogen and its partners in 24 European countries.

Related articles
Alvogen receives European approval for generic lenalidomide

Glenmark gains approval for anti-epileptic generic

Reference
1.  GaBI Online - Generics and Biosimilars Initiative. Mylan launches generic asthma inhaler in UK [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 12]. Available from: www.gabionline.net/Generics/News/Mylan-launches-generic-asthma-inhaler-in-UK

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Alvogen, Astrazeneca, Glenmark

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more